{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:39:24Z","timestamp":1771234764066,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Type 2 diabetes (T2D) is a well\u2010recognised cardiovascular disease (CVD) risk factor, and recent guidelines for the management of T2D include consideration of CVD risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To assess whether contemporary clinical management of Australians with T2D is in accord with recent national and international guidelines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This Australia\u2010specific analysis of the CAPTURE study, a non\u2010interventional, cross\u2010sectional study included adults diagnosed with T2D \u2265180\u2009days prior to providing informed consent and visiting primary or specialist care. Main outcome measures were the use of blood glucose\u2010lowering medications (BGLMs), BGLMs with proven cardiovascular benefits and other CVD medications, stratified by CVD status and care setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 824 Australian participants in the CAPTURE sample, 332 (40.3%) had CVD. Oral BGLMs were used by 83.9% of all participants, most commonly metformin (76.0%), dipeptidyl peptidase\u20104 inhibitors (28.8%), sodium\u2010glucose cotransporter\u20102 inhibitors (SGLT2is; 21.8%) and sulfonylureas (21.7%). Insulin was used by 29.2% of participants. BGLMs with proven CV benefit were used by 22.6%; glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101 RAs) were less commonly used than SGLT2is in all CVD groups, but these drug classes were more often prescribed in specialist than primary care (SGLT2is 25.4 vs 20.7%, GLP\u20101 RAs 3.2 vs 0.8% respectively). Use of non\u2010BGLMs for CVD risk reduction appeared consistent with guidelines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Use of BGLMs with CVD benefits appears low in Australia, irrespective of CVD status. This likely reflects the delay in translation of clinical evidence into contemporary care and prescribing restrictions.<\/jats:p><\/jats:sec>","DOI":"10.1111\/imj.15929","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T16:03:04Z","timestamp":1663344184000},"page":"1796-1805","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cardiovascular disease management in Australian adults with type 2 diabetes: insights from the <scp>CAPTURE<\/scp> study"],"prefix":"10.1111","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0749-7411","authenticated-orcid":false,"given":"Timothy M. E.","family":"Davis","sequence":"first","affiliation":[{"name":"Medical School University of Western Australia, and Fremantle Hospital  Fremantle Western Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter G.","family":"Colman","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Royal Melbourne Hospital University of Melbourne  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Hespe","sequence":"additional","affiliation":[{"name":"General Practice and Primary Care Research, School of Medicine The University of Notre Dame Australia  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"Heywood","sequence":"additional","affiliation":[{"name":"Novo Nordisk  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"d'Emden","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Royal Brisbane and Women's Hospital  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,10,3]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13792"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2015.118"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa215"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01344-0"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-021-01505-3"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"e_1_2_8_9_1","unstructured":"Australian Diabetes Society.Australian Type 2 Diabetes Glycaemic Management Algorithm; 2021. Available from URL:https:\/\/diabetessociety.com.au\/downloads\/20210412%20T2D%20Management%20Algorithm%2001032021.pdf"},{"key":"e_1_2_8_10_1","unstructured":"National Vascular Disease Prevention Alliance.Guidelines for the Management of Absolute Cardiovascular Disease Risk; 2012."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S010"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz486"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-S010"},{"key":"e_1_2_8_14_1","unstructured":"The Royal Australian College of General Practitioners.Management of Type 2 Diabetes: A Handbook for General Practice; 2020. Available from URL:https:\/\/www.racgp.org.au\/getattachment\/41fee8dc-7f97-4f87-9d90-b7af337af778\/Management-of-type-2-diabetes-A-handbook-for-general-practice.aspx"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1288"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2014.0048"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.44.11.1249"},{"key":"e_1_2_8_18_1","unstructured":"Australian Government \u2013 Department of Health Therapeutic Goods Administration.FORXIGA\u00ae Dapagliflozin Propanediol Monohydrate: Product Information; 2021. Available from URL:https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2012-PI-02861-1"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_8_20_1","volume-title":"New TGA Indication for Empagliflozin; 2017","author":"NPS MedicineWise"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01405-y"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000703"},{"key":"e_1_2_8_23_1","unstructured":"Australian Government \u2013 Department of Health Therapeutic Goods Administration.BYETTA\u00ae Exenatide: Product Information; 2013. Available from URL:https:\/\/www.tga.gov.au\/file\/1019\/download"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.31128\/AJGP-02-20-5222"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50756"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.15929","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/imj.15929","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.15929","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T06:30:34Z","timestamp":1697783434000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.15929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,3]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1111\/imj.15929"],"URL":"https:\/\/doi.org\/10.1111\/imj.15929","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,3]]},"assertion":[{"value":"2022-06-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}